Replimune Group, Inc. (NasdaqGS: REPL)
Health Care · Biotechnology · US
$13.21
-1.56% today · +194.3% 1Y
Replimune Group, Inc. (NasdaqGS: REPL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.26B and employs 465 people.
Over the last twelve months the share price has gained 194.3%, trading between 1.50 and 16.33.
Tweenvest scores Replimune Group, Inc. across four factors: quality 36/100, value 54/100. Its strongest factor is value.
REPL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.26B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.15
- Dividend yield
- —
- Beta (5Y)
- 0.94
- 52-week high
- $16.33
- 52-week low
- $1.50
- Avg volume (3M)
- —
- Shares outstanding
- 94.22M
- Employees
- 465
- Next earnings
- —
About Replimune Group, Inc.
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
- ISIN
- US76029N1063
- Founded
- 2015
- Listed since
- Jul 20, 2018
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Liaoning Chengda Biotechnology Co., Ltd.SHSE: 688739 | $1.30B | CN¥21.20 | +0.86% |
| Vcanbio Cell & Gene Engineering Corp., LtdSHSE: 600645 | $1.30B | CN¥19.10 | +2.25% |
| Vitrolife AB (publ)OM: VITR | $1.29B | Skr95.65 | +0.05% |
| Seegene, Inc.KOSDAQ: A096530 | $1.29B | ₩38,150.00 | +3.39% |
| Daan Gene Co., Ltd.SZSE: 002030 | $1.26B | CN¥6.03 | +4.87% |
| Savara Inc.NasdaqGS: SVRA | $1.25B | $4.87 | -1.02% |
| ORIC Pharmaceuticals, Inc.NasdaqGS: ORIC | $1.24B | $12.00 | +0.08% |
| Suzhou Ribo Life Science Co., Ltd.SEHK: 6938 | $1.21B | HK$55.90 | +2.95% |
Figures last refreshed Oct 11, 2026.